(19)

(11)

EP 4 771 023 A2

(12)

(88) Date of publication A3: 10.04.2025 (43) Date of publication: 08.07.2026 Bulletin 2026/28 (21) Application number: 24860682.4 (22) Date of filing: 07.08.2024

(51) International Patent Classification (IPC):  C07F 9/10(2006.01) A61K 31/683(2006.01) (52) Cooperative Patent Classification (CPC): C07F 9/10; A61K 31/683; A61K 45/06 (86) International application number: PCT/US2024/041253 (87) International publication number: WO 2025/049064 (06.03.2025 Gazette 2025/10)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 28.08.2023 US 202318457037 (71) Applicant: Signpath Pharma, Inc. Sandy, UT 84094 (US)	(72) Inventor: LEVY, Daniel, Emil San Mateo, CA 94402 (US) (74) Representative: SONN Patentanwälte GmbH & Co KG  Riemergasse 14 1010 Wien 1010 Wien (AT)